Perceptive Advisors IMMX Position
ActivePerceptive Advisors initiated a new position in Immix Biopharma, Inc. (IMMX) in Q4 2025, holding $1.8M worth of shares across 338,941 shares.
1 other tracked fund also holds IMMX.
There is an upcoming Phase 2 readout for NXC-201 CAR-T in 259 days (Dec 31, 2026), making the timing of Perceptive's position particularly relevant.
About Immix Biopharma, Inc.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
Full company profile →Short Interest
7.2%
4.5 days to cover
Frequently Asked Questions
Does Perceptive Advisors own IMMX?
Yes. As of Q4 2025, Perceptive Advisors holds 338,941 shares of Immix Biopharma, Inc. (IMMX) valued at $1.8M. This data comes from their SEC 13F filing.
How many hedge funds own IMMX?
2 specialist biotech hedge funds currently hold IMMX, including Eventide Asset Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Perceptive Advisors first buy IMMX?
Perceptive Advisors's position in IMMX was first reported in Q4 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Perceptive Advisors's IMMX position increasing or decreasing?
Perceptive Advisors initiated a new position in IMMX in the most recent quarter. This is their first reported holding.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
IMMXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Perceptive AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →